Articles related to BETA-BLOCKERS

“Use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.” — FDA Class II Recall Definition

Beta-blocker use was not associated with reductions in all-cause mortality or cardiovascular mortality compared with the absence of beta-blocker therapy.

Women had a 45% higher relative risk for death, heart attack, or heart failure hospitalization when taking beta-blockers compared to non-beta-blocker groups, with the risk confined to those with preserved LVEF and higher doses.

The FDA says on its website that it has been investigating drugs for nitrosamines in some types of medications, noting they’re common in water and foods. But the agency noted that such impurities have been linked to an increase in cancer in individuals who are exposed to elevated levels and over long periods of time.

“The FDA said the reason for the recall is that the ‘product failed to meet dissolution acceptance criteria in the stability studies at the 6th month.'”

First randomized evidence supporting feasibility of maintaining cardiac stability with carvedilol alone after systematic withdrawal of other heart failure medications in selected patients.